TGN Level Monitoring AZA — SCE Rheumatology MCQ

Correct answer: D — Thioguanine nucleotide (TGN) levels can be measured to assess Azathioprine metabolite levels; low levels may indicate non-adherence or rapid metabolism while high levels predict myelotoxicity

The best answer is “Thioguanine nucleotide (TGN) levels can be measured to assess Azathioprine metabolite levels; low levels may indicate non-adherence or rapid metabolism while high levels predict myelotoxicity”. Thioguanine nucleotide (TGN) levels can be measured to assess Azathioprine metabolite levels; low levels may indicate non-adherence or rapid metabolism while high levels predict myelotoxicity is supported by the cited UK or directly applicable specialist authority and best matches the tested threshold, complication or monitoring principle. The remaining choices—“principally TPMT at baseline, after safety review, after specialist assessment, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist assessment”, “No therapeutic monitoring available, after specialist assessment, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist assessment, with clinical reassessment”, “principally LFTs, with clinical reassessment, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist assessment, with clinical reassessment, within a rheumatology pathway”, “principally FBC monitoring, within a rheumatology pathway, within a rheumatology pathway, after safety review, after specialist assessment, with clinical reassessment, within a rheumatology pathway”—are credible in related rheumatology presentations, but each addresses a different diagnosis, investigation, treatment sequence or complication and does not fit the decisive findings in this stem.

Reference: NICE NG100 rheumatoid arthritis in adults: https://www.nice.org.uk/guidance/ng100/chapter/Recommendations